VKTX
Viking Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
33.91
▼ 0.45 (1.31%)
MARKET · —
Price
Open
35.26
Prev close
34.36
Day high
34.98
Day low
33.48
Volume
1.47M
Market cap
$3.95B
P/E (TTM)
—
52W range
22.96 – 43.15
Trailing performance
Returnvs SPY
1W
+2.11%
+3.5%
1M
-4.24%
-8.0%
3M
+10.46%
+7.4%
6M
+9.22%
-1.8%
YTD
-3.67%
-16.0%
1Y
+31.92%
+11.9%
3Y
+138.66%
+64.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$3.95B
Enterprise value$3.46B
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-534.80M
EPS (TTM)$-4.67
Free cash flow$-230.79M
Total cash$501.66M
Total debt$4.09M
Book value / share$3.50
Shares outstanding116.65M
Float113.73M
Short % of float20.42%
Dividend yield—
Beta (5Y)0.69
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.85
PEG ratio—
Price / sales—
Price / book9.68
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-88.85%
Return on assets-51.86%
Debt / equity1.00
Current ratio4.72
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$359.64M | -$109.96M | -$85.89M | -$68.87M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$359.64M | -$109.96M | -$85.89M | -$68.87M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.21 | -1.10 | +8.9% |
| Mar 2026 | -0.91 | -1.37 | -50.5% |
| Dec 2025 | -0.90 | -1.38 | -53.1% |
| Sep 2025 | -0.67 | -0.81 | -20.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.07 | 16 | $0 | 0.0% |
| Next quarter | -1.10 | 16 | $0 | 0.0% |
| Current year | -4.61 | 16 | $0 | 0.0% |
| Next year | -4.32 | 17 | $0 | 0.0% |
Analyst targets & ownership
Mean target$92.39
High target$125.00
Low target$35.00
Implied upside172.47%
Analyst count19
ConsensusSTRONG BUY
Strong buy / Buy5 / 13
Hold2
Sell / Strong sell0 / 0
Held by insiders3.09%
Held by institutions66.12%
Institutions holding574
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+107.86K
Net buying
Buy transactions
5
295.81K shares
Sell transactions
3
187.95K shares
Net transactions
+8
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
3.61M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | KELLY-GEMMELL DOROTHY ELIZABETH Director |
STOCK | 6.33K | $0 | Direct |
| Jul 29, 26 | ZANTE GREGORY S Chief Financial Officer |
SELL | 21.22K | $710.14K | Direct |
| Jul 29, 26 | LIAN BRIAN Chief Executive Officer |
SELL | 148.52K | $4.95M | Direct |
| Jul 29, 26 | MANCINI MARIANNA Chief Operating Officer |
SELL | 18.22K | $609.64K | Direct |
| Jul 28, 26 | ZANTE GREGORY S Chief Financial Officer |
STOCK | 31.67K | $0 | Direct |
| Jul 28, 26 | LIAN BRIAN Chief Executive Officer |
STOCK | 221.67K | $0 | Direct |
| Jul 28, 26 | MANCINI MARIANNA Chief Operating Officer |
STOCK | 31.67K | $0 | Direct |
| Mar 10, 26 | AUBUCHON NEIL WILLIAM Officer |
BUY | 4.47K | $149.91K | Direct |
| Jan 5, 26 | ZANTE GREGORY S Chief Financial Officer |
SELL | 57.66K | $1.90M | Direct |
| Jan 5, 26 | LIAN BRIAN Chief Executive Officer |
SELL | 233.41K | $7.69M | Direct |
| Jan 5, 26 | MANCINI MARIANNA Chief Operating Officer |
SELL | 57.66K | $1.90M | Direct |
| Jan 2, 26 | FOEHR MATTHEW W Director |
STOCK | 3.15K | $0 | Direct |
| Jan 2, 26 | SINGLETON J MATTHEW Director |
STOCK | 3.15K | $0 | Direct |
| Jan 2, 26 | ZANTE GREGORY S Chief Financial Officer |
STOCK | 73.05K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AUBUCHON NEIL WILLIAM |
Officer | 4.47K | Purchase |
FOEHR MATTHEW W |
Director | 135.19K | Stock Award(Grant) |
KELLY-GEMMELL DOROTHY ELIZABETH |
Director | 6.33K | Stock Award(Grant) |
LIAN BRIAN |
Chief Executive Officer | 2.57M | Sale |
MACARTNEY LAWSON |
Director | 51.12K | Stock Award(Grant) |
MANCINI MARIANNA |
Chief Operating Officer | 422.76K | Sale |
ROUAN SARAH KATHRYN |
Director | 4.39K | Stock Award(Grant) |
ROWLAND CHARLES A JR |
Director | 33.15K | Stock Award(Grant) |
SINGLETON J MATTHEW |
Director | 12.65K | Stock Award(Grant) |
ZANTE GREGORY S |
Chief Financial Officer | 212.20K | Sale |
Moving averages & technicals
SMA 10
33.96
-0.15% from price
SMA 20
33.66
+0.68% from price
SMA 50
35.08
-3.40% from price
SMA 100
33.53
+1.12% from price
SMA 200
33.72
+0.50% from price
EMA 12
34.06
-0.43% from price
EMA 26
34.33
-1.23% from price
EMA 50
34.32
-1.18% from price
RSI (14)
47.9
Neutral
MACD (12,26,9)
-0.28
Hist 0.14
ATR (14)
1.33
3.93% of price
Realised vol 30D
42.8%
Annualised
Bollinger upper
35.41
20, 2σ
Bollinger lower
31.92
20, 2σ
50 / 200 cross
Golden
35.08 vs 33.72
Trend bias
Above 200
+0.50%
Risk profile
Beta vs SPY
1.15
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
42.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-35.5%
Peak to trough
Max drawdown 5Y
-78.9%
Peak to trough
ATR 14
1.33
3.93% of price
Beta (reported)
0.69
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.52
Call-heavy session
Put / call open interest
0.44
Positioning, not flow
Max pain
35.00
+3.3% from spot
ATM implied vol
75.7%
Nearest strike to spot
Skew (10% OTM)
-5.6%
Calls bid over puts
Call volume
1.91K
Contracts, this expiry
Put volume
988
Contracts, this expiry
Heaviest call OI
35.00
334 contracts
Heaviest put OI
35.00
256 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
2 GLP-1 Stocks That Could Double Your Money by 2031
Motley Fool · 6d ago
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
Motley Fool · 14d ago
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
Motley Fool · 16d ago
Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?
Simply Wall St. · 18d ago
The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why
Simply Wall St. · 18d ago
Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says
MT Newswires · 19d ago
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
Motley Fool · 23d ago
Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says
MT Newswires · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.